Payment overview · 2025
General Payments
$1,162.49
86 reported records · 16 companies
Healthcare provider profile · identity verified
John C Showalter, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KNOXVILLE, TN · NPI 1104862002
Verified facts
What the public records show
CMS Open Payments records show John C Showalter, MD received $1,162.49 in general payments during 2025 across 86 reported records.
Novo Nordisk Inc accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Shingrix by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $239.95 | 20.6% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $196.09 | 16.9% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $141.82 | 12.2% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $139.11 | 12.0% | 14 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $82.69 | 7.1% | 4 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $79.34 | 6.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $52.72 | 4.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.03 | 3.8% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $37.83 | 3.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.77 | 2.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.36 | 2.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.12 | 2.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.63 | 1.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.61 | 1.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.57 | 1.2% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.85 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,162.49 | 86 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $131.57 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $128.32 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $121.36 | 13 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $107.70 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $99.91 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $93.03 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $92.92 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $79.99 | 7 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $79.34 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.55 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $54.08 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $52.72 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $44.03 | 3 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $37.83 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.77 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $30.36 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $28.12 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.50 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.50 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $7.22 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $3.26 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $3.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 218 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 135 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
78 | 21 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
218 | 54 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
32 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
135 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
218 | 54 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 770 | 193 |
| Atorvastatin Calcium | Atorvastatin Calcium | 717 | 190 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 529 | 147 |
| Omeprazole | Omeprazole | 435 | 117 |
| Alprazolam | Alprazolam | 425 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 372 | 67 |
| Lisinopril | Lisinopril | 370 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 344 | 93 |
| Zolpidem Tartrate | Zolpidem Tartrate | 311 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 307 | 84 |
| Gabapentin | Gabapentin | 271 | 73 |
| Glimepiride | Glimepiride | 233 | 60 |
| Sertraline Hcl | Sertraline Hcl | 226 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 225 | 58 |
| Mounjaro | Tirzepatide | 222 | 33 |
| Losartan Potassium | Losartan Potassium | 221 | 58 |
| Eliquis | Apixaban | 218 | 54 |
| Metformin Hcl Er | Metformin Hcl | 199 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 57 |
| Metformin Hcl | Metformin Hcl | 185 | 50 |
| Trazodone Hcl | Trazodone Hcl | 185 | 45 |
| Montelukast Sodium | Montelukast Sodium | 181 | 57 |
| Prednisone | Prednisone | 171 | 121 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 58 |
| Simvastatin | Simvastatin | 150 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 45 |
| Carvedilol | Carvedilol | 141 | 39 |
| Meloxicam | Meloxicam | 140 | 46 |
| Ozempic | Semaglutide | 135 | 31 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 121 | 28 |
| Furosemide | Furosemide | 119 | 41 |
| Allopurinol | Allopurinol | 116 | 33 |
| Lorazepam | Lorazepam | 116 | 21 |
| Clonazepam | Clonazepam | 115 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 114 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 31 |
| Azithromycin | Azithromycin | 106 | 87 |
| Donepezil Hcl | Donepezil Hcl | 103 | 25 |
| Irbesartan | Irbesartan | 103 | 29 |
| Benazepril Hcl | Benazepril Hcl | 101 | 29 |
| Estradiol | Estradiol | 94 | 26 |
| Atenolol | Atenolol | 91 | 23 |
| Lovastatin | Lovastatin | 88 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 82 | 26 |
| Potassium Chloride | Potassium Chloride | 82 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 19 |
| Tramadol Hcl | Tramadol Hcl | 80 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 19 |
| Synthroid | Levothyroxine Sodium | 78 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 72 | 17 |
| Jardiance | Empagliflozin | 68 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 21 |
| Celecoxib | Celecoxib | 64 | 19 |
| Valacyclovir | Valacyclovir Hcl | 63 | 31 |
| Bupropion Hcl Sr | Bupropion Hcl | 60 | 16 |
| Warfarin Sodium | Warfarin Sodium | 59 | 16 |
| Chlorthalidone | Chlorthalidone | 58 | 18 |
| Fluconazole | Fluconazole | 55 | 27 |
| Mirtazapine | Mirtazapine | 55 | 17 |
| Valsartan | Valsartan | 55 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 15 |
| Spironolactone | Spironolactone | 54 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 14 |
| Xarelto | Rivaroxaban | 50 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 15 |
| Telmisartan | Telmisartan | 48 | 16 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 47 | 11 |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Ibuprofen | Ibuprofen | 46 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 45 | 17 |
| Clonidine Hcl | Clonidine Hcl | 44 | 21 |
| Finasteride | Finasteride | 44 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | 12 |
| Temazepam | Temazepam | 44 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 42 | 14 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 41 | 12 |
| Nystatin | Nystatin | 41 | 15 |
| Famotidine | Famotidine | 40 | 11 |
| Ramipril | Ramipril | 39 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Fenofibrate | Fenofibrate | 36 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 36 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 36 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | 16 |
| Cefdinir | Cefdinir | 33 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 32 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 18 |
| Azelastine Hcl | Azelastine Hcl | 32 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 24 |
| Acyclovir | Acyclovir | 31 | 12 |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Ibu | Ibuprofen | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 11 |
| Promethazine Hcl | Promethazine Hcl | 22 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 17 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,162.49 · 86 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, CAMZYOS, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, FFRct, FREESTYLE LIBRE 3, GEMTESA, HORIZANT, KRYSTEXXA, LINZESS, MINIMED 780G, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VRAYLAR, Veozah, Wegovy, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error